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substantial degree of association between the two patch tests
(relative risk: 4.89, 95% con®dence interval (CI): 4.22±5.67).
Interestingly, the proportion of ``oakmoss'' positive patients
(``+'' to ``+++'') increased from 5.4% in patients not reacting
to colophony, to 14.7% in those reacting with erythema only
(``?''), to 19.4% in those with a ``+'' reaction, to 30.0% in
those with a ``++'' reaction, and to 53.3% in those with very
strong (``+++'') reactions to colophony (Cochran-Armitage
trend test: p < 0.0001), see Table I. To further address the
question of concordance, i.e., whether the two tests yield more
or less identical results, we calculated Cohen's kappa (Cohen,
1960). This standard measure in such analyses quanti®es the
chance-corrected proportion of agreement between two discrete
ratings and gives a more informative quantitative summarization
of concordance than the crude proportion of agreement for
skewed distributions of ratings as in this case (Fleiss, 1981).
Although 87.1% of the patients showed identical patch test
results for both tests, the kappa value is only 0.13 (95% CI:
0.11±0.15) indicating a very low degree of concordance beyond
chance.
While the analytical results of Lepoittevin et al (2000) give
some insight into the pitfalls in patch testing (with natural
materials), we have some reservations concerning the practical
conclusions that can be drawn from these observations. First of
all, the magnitude of the problem in practice and its relevance
seems to be considerably smaller than indicated by their study.
Actually, the small sample size (n = 17) makes these results quite
imprecise (the exact 95% CI accompanying 52.9% as derived
from ``9 out of 17'' is 27.8%±77.0%, the lower limit being not
far away from our estimate of 27.0% (exact 95% CI: 23.6%±
30.6%). Concerning cross-reactivity, concordance beyond
chance is very limited considering the whole group of patients.
The strong association between the degree of sensitization to
colophony and ``oakmoss'' reactivity, however, could support
the notion of minute traces of resin acids present in ``oakmoss''
being capable of eliciting a positive reaction at least in patients
with extreme sensitivity to colophony. Of course, nonspeci®c
mechanisms like the ``angry back syndrome'' must also be
considered if any very strong reaction is observed, and, indeed
(very) strong reactions are generally associated with an increased
number of concomitant patch test reactions (J. Brasch, personal
communication, 2000).
Last but not least the possibility of concurrent sensitization to
``oakmoss'' and ``treemoss'', which are used together in
perfumes (Dahlquist and Fregert, 1980) ± intentionally or
unintentionally (by using ``oakmoss'' raw material that is often
blended with the cheaper ``treemoss'' material) ± had not been
taken into account by Lepoittevin et al (2000). In principle,
highly puri®ed patch test material should be used to standardize
patch testing wherever possible ± and necessary. The question
remains: is pure ``oakmoss'' patch test material a necessity, in
view of the largely combined clinical exposure to ``oakmoss''
and ``treemoss'', or, conversely, is not ``contaminated'' patch test
material even more adequate to sensitively diagnose relevant
sensitization?
Wolfgang Uter, Olaf Gefeller,* Johannes Geier, Axel Schnuch
(for the IVDK1)
Information Network of Departments of Dermatology (IVDK),
Georg August University, Department of Dermatology,
GoÈttingen, Germany
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We read with interest the letter from Uter et al. (2001) on the
concordance between ``oakmoss'' and colophony in clinical patch
testing.
The aim of our paper (Lepoittevin et al. 2000) was to see if patients
with a well-established allergy to colophony could react when tested
with usual concentrations of ``oakmoss'' due to the presence of resin
acids and their oxidation products. The 17 patients included in our
study were therefore selected on the base of their known past and
relevant allergy to colophony. The aim of our study was never to
evaluate the percentage of concordance between oakmoss and
colophony on a large population but to draw attention to a possible
misdiagnosis due to the presence of impurities in patch test material.
Table I. Patch test results with colophony (20% pet.) and
``oakmoss'' (1% pet., both by Trolab) in 12614 patients
between 1992 and 1999
``Oakmoss''
Sum/(%)
Colophony neg. ?/IR + ++ +++ Colophony
neg. 10905 253 416 164 55 11793
(93.5%)
?/IR 134 17 19 5 2 177
(1.4%)
+ 261 21 41 20 7 350
(2.8%)
++ 130 22 45 20 0 217
(1.7%)
+++ 34 2 15 18 8 77
(0.6%)
Sum/(%) 11464 315 536 227 72 12614
``Oakmoss'' (90.9%) (2.5%) (4.2%) (1.8%) (0.6%) (100.0%)
Reprint requests to: Dr. Jean-Pierre Lepoittevin, Clinique Dermato-
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1Centers of the IVDK contributing to this analysis (in alphabetical order):
Aachen (H. Dickel), Augsburg (O. Hirschsteiner, A. Ludwig), Berlin B.
Franklin (B. Tebbe, R. Treudler), Berlin ChariteÂ (B. Laubstein, J. Grabbe,
T. Zuberbier), Berlin UKRV (J. Grabbe, T. Zuberbier), Bochum (C.
Szliska), Dortmund (P.J. Frosch, B. Pilz, C. Pirker), Dresden (G. Richter),
Duisburg (J. Schaller), Erlangen (K.P. Peters, M. Fartasch), Essen (H.-M.
Ockenfels, U. Hillen), GoÈttingen (Th. Fuchs), Graz (W. Aberer, B.
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Rakoski), NuÈrnberg (I. MuÈller), OsnabruÈck (W. Uter), Rostock (H.
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In that respect, it is interesting to note in the letter from Uter
et al. (2001) that the percentage of colophony sensitive patients
reacting to oakmoss is increasing with regard to the severity of their
allergy. Thus the percentage of patients reacting to oakmoss is
14.7% in patients reacting to colophony with erythema only (``?''),
19.4% in those with a ``+'' reaction, 30% in those with a ``++''
reaction, and 53.3% in those with very strong (``+++'') reactions.
This later ®gure is very similar to the one we observed (53%) on
our selected patients.
We suggest that more care should be taken when stating that
12823 patients were patch tested between 1992 and 1999 to the
same oakmoss material as the one we have been using in our study.
Over a period of time patch test suppliers will use different batches
of oakmoss material either from the same supplier or from different
suppliers. The oak moss sample we have been using is identical to
the material used by Trolab (Reinbek, Germany) from 1999 to
now. Therefore a comparison of data can only be valid if conducted
in the period 1999±2000.
We are of course well aware that oakmoss and treemoss are skin
sensitizers, not only because of the presence of resin acids but also
because of the presence of other sensitizers, some of which are
known in the literature (Dahlquist et al., 1980). Among our 17
patients two reacted to the oakmoss from Chemotechnique
(MalmoÈ, Sweden), despite a low content of resin acid, which
probably indicates a true co-sensitization to oakmoss and
colophony.
Jean-Pierre Lepoittevin, An Goossens*
Laboratoire de Dermatochimie, UniversiteÂ Louis Pasteur,
Clinique Dermatologique, Strasbourg Cedex, France
*Department of Dermatology, University Hospital of Leuven,
Leuven, Belgium
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Staphylococcal Colonization in Atopic Dermatitis Treatment
with Topical Tacrolimus (Fk506)
To the Editor:
Tacrolimus (FK506) is a potent immunosuppressive macrolide.
Clinical trials have demonstrated that it is an effective topical
treatment for atopic dermatitis (AD) in adults as well as in children
(Ruzicka et al, 1997; Boguniewicz et al, 1998). Experience from
these trials suggests that an ephemeral burning sensation is the most
common drug-related side-effect; however, skin infections are a
potential complication of local treatment with topical immuno-
suppressive agents, and a recent open-label multicenter study,
involving 316 AD patients treated with 0.1% tacrolimus ointment
for 6±12 months, observed skin infections at the application site in
19.8% of patients (Reitamo et al, 2000). Heavy skin colonization
with Staphylococcus aureus is well established in patients with AD,
even in the absence of clinical signs of skin infection, and also on
normal skin (Hauser et al, 1985; Lever et al, 1988).
As tacrolimus has no antistaphylococcal activity in vitro (Kino et al,
1987), topical treatment with FK-506 might enhance S. aureus
colonization by a local immunosuppressive mechanism. Therefore,
we conducted a pilot study in order to determine the in¯uence of
treatment with 0.1% tacrolimus ointment on S. aureus colonization.
Tacrolimus ointment 0.1% was formulated according to Aoyama
et al (1995).
In 11 patients (mean age 23.2 [SD 13.8]) diagnosed with AD
according to the criteria of Hanni®n and Rajka (1980), we
identi®ed 40 lesional skin sites positive for S. aureus colonization.
All patients had stopped systemic or topical antibiotic treatments at
least 2 wk before onset of treatment with 0.1% tacrolimus
ointment; the use of emollients was allowed throughout the study
period. Staphylococcus aureus colonization density was measured as
the number of agglutination-positive colony forming units (CFU
per cm2) (Pastorex Staph-plus, Sano® Pasteur, Marnes La Coquette,
France), sampled with a mannitol salt agar contact plate (Ecobion,
Carouge, Switzerland). Assessment of S. aureus colonization density
at each site was done at baseline (day 0), and scheduled on days 3, 7,
14, and 21 after the onset of 0.1% tacrolimus ointment
monotherapy. In total, 151 samples were realized, which represents
75.5% of the scheduled number (n = 200). Of these, 139 samples
(92.1%) could be evaluated; 7.9% of the realized samples could not
be processed because of technical problems. We also studied 11 S.
aureus positive lesional skin sites in 11 patients (mean age 27.3 [SD
9.5]) that were treated with the vehicle alone. In order to correlate
S.aureus colonization density at each site with parameters of
treatment ef®cacy, we performed clinical grading based on the
lesional score of the SCORAD index (Consensus report ETFAD),
and assessed transepidermal water loss (TEWL), a parameter of skin
barrier function (EP2 evaporimeter, ServoMed AB, Kinna,
Sweden). Statistical comparison was made using the Wilcoxon
signed-rank test, a nonparametric test; rank correlation analysis was
made using the Spearman test.
During treatment with 0.1% tacrolimus ointment, TEWL and
lesional score showed a signi®cant decrease already after the third
day of therapy (p < 0.03 and p < 0.001, respectively), whereas
decrease of S. aureus colonization became signi®cant at treatment
day 7 (p < 0.003) (Fig 1). Statistical analysis according to the
Spearman test showed no correlation between the three parameters
(score, TEWL, and S. aureus colonization) studied at days 0, 3, 7,
14, and 21. In 31 samples, signi®cant but transient increases of
S. aureus CFU counts, as compared with preceding levels at the
same skin site, were observed at some point during the 21-d
treatment period (p < 0.05), without simultaneous changes of the
clinical score and TEWL.
Our results demonstrate that topical immunosuppressive therapy
of AD with 0.1% tacrolimus ointment during 3 wk is associated
with an overall decrease of S. aureus colonization on lesional skin.
Similar results have been reported with local steroid monotherapy,
which has also been shown to reduce S. aureus colonization on AD
skin (Nilsson et al, 1992). These ®ndings are consistent with the
concept of in¯ammatory skin condition in AD, being itself a
predisposing factor for colonization with S. aureus. This hypothesis
has some limitation insofar as the day-to-day variation of S. aureus
colonization in untreated skin of patients with AD is not known. As
tacrolimus does not have a direct antistaphylococcal activity (Kino
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